Strategies for Managing Treatment-Naïve CLL with High-Risk Features
Joanna Rhodes, MD, MSCE, explores the general approach to treatment-naïve CLL patients with high-risk factors such as del17p and TP53 mutations.
Joanna Rhodes Exploring Therapeutic Advancements Chronic Lymphocytic Leukemia Managing Treatment Na Treatment Naive Cll Treatment Naive Chronic Lymphocytic Leukemia
Source: onclive.com